This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Stealth BioTherapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

3.3%

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	30.9%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:S1BA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2024	N/A	-48	N/A	N/A	1
12/31/2023	N/A	-48	N/A	N/A	1
12/31/2022	N/A	-47	N/A	N/A	1
12/31/2021	N/A	-53	-45	-45	N/A
9/30/2021	N/A	-51	N/A	N/A	N/A
6/30/2021	N/A	-56	-44	-44	N/A
3/31/2021	N/A	-50	N/A	N/A	N/A
12/31/2020	N/A	-57	-54	-54	N/A
9/30/2020	21	-35	-39	-38	N/A
6/30/2020	21	-41	N/A	N/A	N/A
3/31/2020	21	-44	N/A	N/A	N/A
12/31/2019	21	-72	-48	-48	N/A
9/30/2019	N/A	-102	-75	-74	N/A
6/30/2019	N/A	-108	N/A	N/A	N/A
3/31/2019	N/A	-120	N/A	N/A	N/A
12/31/2018	N/A	-97	-72	-72	N/A
9/30/2018	N/A	-92	-69	-69	N/A
12/31/2017	N/A	-83	-70	-70	N/A

애널리스트 미래 성장 예측

수입 대 저축률: S1BA is forecast to remain unprofitable over the next 3 years.

수익 vs 시장: S1BA is forecast to remain unprofitable over the next 3 years.

고성장 수익: S1BA is forecast to remain unprofitable over the next 3 years.

수익 대 시장: Insufficient data to determine if S1BA's revenue is forecast to grow faster than the German market.

고성장 수익: S1BA is forecast to have no revenue next year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if S1BA's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Stealth BioTherapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Stealth BioTherapeutics Corp(NasdaqGM:MITO) dropped from NASDAQ Composite Index

J. Wood Capital Advisors LLC and Morningside Venture (I) Investments Limited completed the acquisition of 22.5293% stake in Stealth BioTherapeutics Corp (NasdaqGM:MITO).

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis

Stealth BioTherapeutics Corp Announces Departure of Robert Weiskopf as Chief Financial Officer

Stealth BioTherapeutics Announces Receipt of Non-Compliance Notice from Nasdaq

Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium

Stealth BioTherapeutics Corp Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022

Stealth Biotherapeutics Announces Data from Reclaim-2 Phase 2 Trial of Elamipretide in Geographic Atrophy

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces New SBT-272 Data and Trial Initiation

Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Requirement

Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid and Market Value Requirements

Stealth Bio Therapeutics Provides Update on Clinical Stage Rare Disease Programs

Stealth BioTherapeutics Corp Presents Positive Elamipretide Data in Pediatric Cardiology At International Society for Heart Research North American Section Meeting 2021

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021

Stealth Biotherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome

Stealth Biotherapeutics Corp Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration At the 2021 Arvo Annual Meeting

Stealth BioTherapeutics Corp Announces Promotion of Marty Redmon to Chief Research & Development Officer

Stealth BioTherapeutics Corp Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy

New 90-day high: €1.53

New 90-day high: €1.39

Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As Treatment For Cardiomyopathy In Barth Syndrome

New 90-day high: €1.27

Stealth BioTherapeutics Corp Announces Board and Committee Changes

New 90-day low: €1.02

Revenue in line with expectations

New 90-day low: €1.03

Revenue in line with expectations

Stealth Biotherapeutics Announces Development Financing to Advance Elamipretide Clinical Trials

Stealth BioTherapeutics Corp to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €1.08

Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting

New 90-day low - €1.21

New 90-day low - €1.46

Stealth BioTherapeutics Corp to Report Q2, 2020 Results on Aug 06, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견